BASi Reports Fiscal 2012 First Quarter Results

Marketwired

WEST LAFAYETTE, IN--(Marketwire -02/10/12)- Bioanalytical Systems, Inc. (NASDAQ: BASI - News) (BASi) today announced financial results for the first quarter of fiscal 2012.

For the three months ended December 31, 2011, revenue decreased 7.1% to $7,516,000 compared to $8,090,000 for the first quarter of fiscal 2011. The net loss for the first quarter of fiscal 2012 was $1,491,000, or $0.21 per share, compared to net income of $310,000, or $0.06 per share, for the first quarter of fiscal 2011.

Cash flow from operations was $590,000 for this year's first quarter compared to $737,000 for the first fiscal quarter of 2011.

At December 31, 2011, BASi reported cash and cash equivalents of $2,412,000, total long-term obligations of $1,118,000, and shareholders' equity of $14,173,000, or $2.03 per outstanding share. Current liabilities at December 31, 2011 included mortgage debt of approximately $6,300,000 that matures in November 2012. The Company intends to refinance this amount in lieu of making balloon payments for the remaining principal balances. At September 30, 2011, cash and cash equivalents were $2,963,000, working capital was $526,000, total long-term obligations were $6,913,000, and shareholders' equity was $15,586,000, or $2.26 per outstanding share.

CEO Comments
"Revenue in the first quarter was below our expectations, primarily because of the delay of a large toxicology contract during the period. Together with the planned increase in staff and equipment associated with our capacity expansion program and new initiatives in support of our clients' drug discovery efforts, including the recently launched Discovery Center located in our headquarters facility in West Lafayette, this resulted in a sharp decrease in gross margin. During the first quarter, we also expanded the sales team for our European operations and increased our advertising and marketing spending as compared to the first three months of fiscal 2011, in line with our strategic growth plan. We do not expect any further increases in our cost structure in coming quarters and are exploring ways to reduce operating costs in the future. We believe that the investments we already have made in our laboratory capabilities and capacity, corporate infrastructure, and marketing program will support higher revenue beginning in the current quarter," said President and CEO Tony Chilton.

Dr. Chilton added, "New drug discovery and development rely increasingly on outsourcing. We are taking advantage of BASi's more than 35 years of contract research experience to expand our business with the growing population of small biotech and pharmaceutical companies that have become a major force in new drug discovery, even as we build our historically close relationships with major pharmaceutical clients. In the first quarter, we invested to develop our capabilities to attract and deliver on profitable new business we are aiming for going forward. We are confident that this is the right strategy to grow our company and increase value for our shareholders."

Earnings Conference Call
BASi has scheduled a conference call at 11:00 a.m. EST this morning to discuss its results for the quarter. To participate in the call, dial 866.383.8009, passcode #52616162 five minutes before the start of the call. A simultaneous webcast may be accessed from the Investors tab at www.BASinc.com. The webcast will be available for replay after 2:00 p.m. EST at this same Internet address. For a telephone replay, dial 888.286.8010, passcode #91679385 after 2:00 p.m. EST.

About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

[SEE BELOW FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS]

 

                        BIOANALYTICAL SYSTEMS, INC.
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      AND COMPREHENSIVE INCOME (LOSS)
            (In thousands, except per share amounts) (Unaudited)


                                                    Three Months Ended
                                                       December 31,
                                               ----------------------------
                                                    2011           2010
                                               -------------  -------------
Service revenue                                $       5,611  $       6,143
Product revenue                                        1,905          1,947
                                               -------------  -------------
    Total revenue                                      7,516          8,090

Cost of service revenue                                5,256          4,668
Cost of product revenue                                  778            706
                                               -------------  -------------
    Total cost of revenue                              6,034          5,374

Gross profit                                           1,482          2,716
Operating expenses:
  Selling                                                998            685
  Research and development                               178            112
  General and administrative                           1,608          1,381
                                               -------------  -------------
    Total operating expenses                           2,784          2,178

Operating income (loss)                               (1,302)           538

  Interest expense                                      (189)          (235)
  Other income                                            --              7
                                               -------------  -------------
Income (loss) before income taxes                     (1,491)           310

Income taxes                                              --             --
                                               -------------  -------------

Net income (loss)                              $      (1,491) $         310

Other comprehensive income (loss):
  Foreign currency translation adjustment                 (1)           (16)
                                               -------------  -------------

Comprehensive income (loss)                    $      (1,492) $         294
                                               =============  =============

Basic net income (loss) per share              $       (0.21) $        0.06
Diluted net income (loss) per share            $       (0.21) $        0.06

Weighted common shares outstanding:
  Basic                                                6,946          4,915
  Diluted                                              6,946          4,981



                        BIOANALYTICAL SYSTEMS, INC.
                   CONDENSED CONSOLIDATED BALANCE SHEETS
                    (In thousands, except share amounts)


                                                December 31,  September 30,
                                                    2011           2011
                                               -------------  -------------
                    Assets                      (Unaudited)

Current assets:
  Cash and cash equivalents                    $       2,412  $       2,963
  Accounts receivable:
    Trade                                              3,353          4,073
    Unbilled revenues and other                        1,263          1,116
  Inventories                                          1,862          1,636
  Refundable income taxes                                  6             --
  Prepaid expenses                                       501            585
                                               -------------  -------------

      Total current assets                             9,397         10,373

Property and equipment, net                           20,751         20,399
Goodwill                                               1,383          1,383
Intangible assets, net                                    46             54
Debt issue costs                                          48             75
Other assets                                              60             62
                                               -------------  -------------

      Total assets                             $      31,685  $      32,346
                                               =============  =============


     Liabilities and shareholders' equity

Current liabilities:
  Accounts payable                             $       2,643  $       1,764
  Accrued expenses                                     1,901          1,762
  Customer advances                                    3,591          3,571
  Income tax accruals                                     16             56
  Revolving line of credit                             1,253          1,346
  Current portion of capital lease obligation            601            613
  Current portion of long-term debt                    6,389            735
                                               -------------  -------------

      Total current liabilities                       16,394          9,847

Capital lease obligation, less current portion         1,118          1,071
Long-term debt, less current portion                      --          5,842

Shareholders' equity:
  Preferred shares, authorized 1,000,000
   shares, no par value:
    2,135 Series A shares at $1,000 stated
     value issued and outstanding at December
     31, 2011 and at September 30, 2011                2,135          2,135
  Common shares, no par value:
    Authorized 19,000,000 shares; 6,972,765
     issued and outstanding at December 31,
     2011 and 6,945,631 at September 30, 2011          1,705          1,698
  Additional paid-in capital                          19,480         19,408
  Accumulated deficit                                 (9,197)        (7,706)
  Accumulated other comprehensive income                  50             51
                                               -------------  -------------

      Total shareholders' equity                      14,173         15,586
                                               -------------  -------------

      Total liabilities and shareholders'
       equity                                  $      31,685  $      32,346
                                               =============  =============

Rates

View Comments (0)